title: Churg-Strauss syndrome: is there an association with leukotriene modifiers?
authors.forename: S
authors.initials: S
authors.lastname: Stoloff
authors.forename: D A
authors.initials: DA
authors.lastname: Stempel
mesh_terms: D000085:Acetates / Q000009:adverse effects; D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000009:adverse effects*; D001249:Asthma / Q000188:drug therapy; D015267:Churg-Strauss Syndrome / Q000139:chemically induced*; D003521:Cyclopropanes; D006801:Humans; D007211:Indoles; D020024:Leukotriene Antagonists / Q000009:adverse effects*; D048448:Phenylcarbamates; D011804:Quinolines / Q000009:adverse effects; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000009:adverse effects
chemical_list: D000085:Acetates; D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D011804:Quinolines; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds; C093875:montelukast; C062735:zafirlukast